Home / Stocks / Eris Lifesciences Limited
ERIS

Eris Lifesciences Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,329.0

Change

-8.1 (-0.61%)

Open

₹1,327.8

Prev. Close

₹1,337.1

Day High

₹1,344.7

Day Low

₹1,315.1

Volume Analysis

Traded

37,385

Delivered

22,640

Delivery %

60.56%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (35.0%)

Weaknesses (0)

No signal for this stock

Opportunities (2)

  • •Strong 3-year EPS growth (16.8%)
  • •Strong 3-year revenue growth (22.9%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,373.7 ₹1,359.2 ₹1,344.1 ₹1,329.6 ₹1,314.5 ₹1,300.0 ₹1,284.9
Fibonacci ₹1,359.2 ₹1,347.89 ₹1,340.91 ₹1,329.6 ₹1,318.29 ₹1,311.31 ₹1,300.0
Camarilla ₹1,337.14 ₹1,334.43 ₹1,331.71 ₹1,329.6 ₹1,326.29 ₹1,323.57 ₹1,320.86

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-11.48%

1 Week

+4.01%

1 Month

+16.96%

3 Months

+0.06%

6 Months

-1.1%

1 Year

-20.4%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹548.5

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

16.18%

Net margin 21.56% × asset turnover 0.41x × equity multiplier 1.83x

Company Overview

Sector

Healthcare

Market Cap

₹18,448 Cr

P/E (TTM)

24.7

ROE

18.7%

Book Value

₹299.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Eris Lifesciences Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 68/100. The strongest factor is Business Quality (86/100), while Momentum (39/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (35.0%). FII holding has been falling.

TopFund Score — Fundamentals Quality

68/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

83

Growth

85

Valuation

49

Cash Flow

48

Corporate Governance

83

Momentum

39

Institutional Ownership

49

Business Quality

86

Risk & Volatility

55

Liquidity

70

From Screener.in

  • −Stock is trading at 4.45 times its book value
  • −Tax rate seems low
  • −Company might be capitalizing the interest cost

Not investment advice — an automated read of public fundamentals data, for research context only.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 505 486 551 720 741 727 705 773 792 807 757 873 892
Expenses + 324 311 402 470 477 477 453 496 504 526 484 577 584
Operating Profit 181 176 148 250 265 250 252 277 288 282 272 296 308
OPM % 36.0% 36.0% 27.0% 35.0% 36.0% 34.0% 36.0% 36.0% 36.0% 35.0% 36.0% 34.0% 35.0%
Other Income + 3 4 15 2 5 4 8 4 3 -17 2 2 -33
Interest 16 18 33 60 59 57 54 49 50 49 46 47 46
Depreciation 42 46 54 76 80 81 77 71 69 70 70 72 73
Profit before tax 126 116 77 116 129 116 129 161 173 145 159 179 156
Tax % 3.0% 12.0% -4.0% 22.0% 25.0% 25.0% 21.0% 22.0% 22.0% 25.0% -75.0% 20.0% -20.0%
Net Profit + 122 101 80 90 96 87 102 125 134 109 279 143 187
EPS in Rs 9 8 5 6 7 6 7 9 9 7 20 10 13
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 10 15 37 54 47 50 28 7 7 11 7 13 13

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 546 597 750 856 982 1,074 1,212 1,347 1,685 2,009 2,894 3,129 3,330
Expenses + 427 425 480 533 637 702 781 858 1,146 1,332 1,876 2,009 2,171
Operating Profit 118 172 269 322 345 372 431 489 539 677 1,018 1,120 1,158
OPM % 22.0% 29.0% 36.0% 38.0% 35.0% 35.0% 36.0% 36.0% 32.0% 34.0% 35.0% 36.0% 35.0%
Other Income + 7 3 25 26 31 12 9 22 9 22 18 -9 -45
Interest 0 0 1 11 23 2 2 4 26 85 231 193 188
Depreciation 16 20 23 26 36 50 43 65 117 183 315 280 285
Profit before tax 109 154 270 312 317 331 394 442 405 431 489 639 640
Tax % 18.0% 13.0% 9.0% 6.0% 8.0% 11.0% 10.0% 8.0% 8.0% 8.0% 23.0% -1.0% —
Net Profit + 89 135 247 295 291 297 355 406 374 397 375 648 718
EPS in Rs 6 10 18 21 21 22 26 30 28 29 26 45 51
Dividend Payout % 0.0% 63.0% 0.0% 0.0% 0.0% 13.0% 21.0% 20.0% 26.0% 0.0% 28.0% 16.0% —
Sales growth 7 9 26 14 15 9 13 11 25 19 44 8 11

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 266 299 553 848 1,137 1,283 1,563 1,895 2,182 2,573 2,841 3,889 4,130
Borrowings + 1 0 1 377 176 0 7 84 877 2,781 2,478 2,359 2,430
Other Liabilities + 91 98 124 170 175 205 202 233 337 1,366 1,415 861 1,007
Total Liabilities 357 397 692 1,408 1,502 1,502 1,785 2,226 3,410 6,734 6,747 7,123 7,581
Fixed Assets + 72 71 232 771 761 875 854 918 2,568 4,319 5,306 5,188 4,869
CWIP 0 0 0 0 3 4 2 27 22 20 67 171 395
Investments 167 190 303 365 356 78 294 520 37 16 67 62 60
Other Assets + 119 136 157 271 383 544 636 761 783 2,379 1,307 1,702 2,257
Total Assets 357 397 692 1,408 1,502 1,502 1,785 2,226 3,410 6,734 6,747 7,123 7,581
Equity Capital 0 0 14 14 14 14 14 14 14 14 14 14 14

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 90 131 200 235 223 271 375 378 292 486 1,065 538
Cash from Investing Activity + -92 -44 -184 -590 -5 123 -323 -320 -975 -1,828 -78 -369
Cash from Financing Activity + 0 -84 -24 363 -221 -335 -82 -45 688 1,380 -881 -314
Net Cash Flow -2 4 -8 8 -3 60 -30 14 5 38 105 -145
Free Cash Flow 77 108 150 210 186 125 350 258 -550 357 910 241
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 96 97 94 94 85 87 103 94 68 87 114 59

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 54.9% → 54.74%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 17.41% 15.2% 14.3% 18.47% 18.73% 18.64% 18.59% 18.57% 17.97% 19.33% 19.39% 19.32%
Promoters 54.9% 54.9% 54.88% 54.87% 54.86% 54.85% 54.83% 54.85% 54.85% 53.92% 54.14% 54.74%
FII 13.13% 14.27% 14.59% 8.01% 8.36% 8.43% 8.39% 7.21% 6.85% 6.39% 5.76% 5.74%
DII 14.55% 15.63% 16.23% 18.64% 18.07% 18.07% 18.18% 19.36% 20.31% 20.35% 20.71% 20.19%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Eris Lifesciences Limited (this stock) 18,448 24.7 4.45 18.7%
Onesource Specl Pharma L 18,464 1614.0 3.12 -1.09%
Syngene International Ltd 17,935 67.5 3.7 7.78%
Caplin Point Lab Ltd. 17,863 25.9 4.58 20.9%
Alivus Life Sciences Ltd 17,803 50.6 — —
Shilpa Medicare Ltd 17,616 55.1 6.39 9.3%
Pfizer Ltd 17,601 115.0 12.74 19.8%

Which Mutual Funds Hold Eris Lifesciences Limited?

Frequently Asked Questions about Eris Lifesciences Limited

Community Sentiment

What are other investors saying about Eris Lifesciences Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.